“Her leadership will accelerate our mission to translate the novel mechanism of Rycals® into innovative therapeutics for heart failure and RYR1-RM patients.” Dr. Tarka is trained as a ...

RyCarma Therapeutics, Inc., a clinical-stage biotech company developing first-in-class small molecule therapeutics for cardiovascular and skeletal muscle diseases, has appointed Elizabeth Tarka, M.D., ...